While application of recombinant IL-1 exerted anti-tumor effects in a number of mouse studies (see above), in several clinical trials systemic application of IL-1 yielded only poor effects on hematopoiesis and tumor development, but significant toxicity [184]. This evidence concerns the gene IL1B and neoplasm.